Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole 10 mg vs 20 mg once daily in non-erosive reflux disease (NERD)
jRCT2080220396Phase 3
- Sponsor
- AstraZeneca
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on jRCT2080220396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220396.